Tradestie Institutional Equity Comparison Engine
NTLA vs VCEL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VCEL Overall Edge
VCEL Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vericel Corporation (VCEL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NTLA trades at N/M Forward P/E with -826.0% operating margin (-48.0% YoY revenue) versus VCEL at 60.5x Forward P/E and 8.3% operating margin (+26.5% YoY). In options structure, NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro) against VCEL sits in SURGE (13th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
VCEL
NTLA N/M vs VCEL 60.5x Fwd P/E
Growth & Margin Winner
VCEL
Op Margin -826.0% vs 8.3% ยท YoY -48.0% vs +26.5%
Momentum & Technical Winner
VCEL
1Y +15.3% vs +43.8% ยท 52W Pos 20% vs 92%
Options & Structure Winner
VCEL
BREAKDOWN (78th %ile IV) vs SURGE (13th %ile IV)
NTLA
NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap
$1.5B
1M Return
-12.43%
1Y Return
+15.34%
Forward P/E
N/M
Unified AI Score
49.9 / 100
HOLD
Tech 47.0
Fund 55.0
Flow 59.0
Mom 60.0
VCEL
NASDAQ
Vericel Corporation
Biological Products, (No Disgnostic Substances)
$57.27
+0.54% 1D
Market Cap
$2.9B
1M Return
+42.71%
1Y Return
+43.75%
Forward P/E
60.5x
Unified AI Score
35.6 / 100
SELL
Tech 50.0
Fund 32.0
Flow 70.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NTLA +15.34%
VCEL +43.75%
Spread: +28.41 pp (VCEL Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NTLA Revenue | VCEL Revenue | NTLA Op. Margin | VCEL Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | $90M | -298.6% | -4.3% | VCEL |
| FY2019 | $40M | $120M | -246.8% | -9.5% | VCEL |
| FY2020 | $60M | $120M | -235.5% | 1.9% | VCEL |
| FY2021 | $30M | $150M | -810.4% | -5.1% | VCEL |
| FY2022 | $50M | $160M | -879.0% | -10.4% | VCEL |
| FY2023 | $40M | $200M | -1420.5% | -3.3% | VCEL |
| FY2024 | $60M | $240M | -923.1% | 1.9% | VCEL |
| FY2025 | $70M | $280M | -651.7% | 4.0% | VCEL |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NTLA | VCEL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.5B | $2.9B | Larger Scale | VCEL |
| Trailing P/E Ratio Valuation | N/M | 90.3x | Lower Multiple | VCEL |
| Forward P/E Ratio Valuation | N/M | 60.5x | Lower Multiple | VCEL |
| Revenue Growth (YoY) Growth | -48.0% | +26.5% | Higher Growth | VCEL |
| Operating Margin (TTM) Profitability | -826.0% | 8.3% | Higher Margin | VCEL |
| Net Profit Margin Profitability | 0.0% | 10.3% | Higher Margin | VCEL |
| Return on Equity (ROE) Capital Efficiency | -62.6% | 9.4% | Higher ROE | VCEL |
| 52-Week Range Position Momentum | 20% ($8โ$18) | 92% ($29โ$60) | Stronger Trend | VCEL |
| Beta / 30D Volatility Risk Regime | 2.30ฮฒ ยท 87% Vol | 0.30ฮฒ ยท 74% Vol | Lower Realized Risk | VCEL |
| Unified Institutional Score Composite Signal | 49.9 / 100 (HOLD) | 35.6 / 100 (SELL) | Higher Composite | NTLA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NTLA vs VCEL Buy Guide
NTLA
BREAKDOWN
94d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
78th %ile
IV Regime
Elevated (60thโ80th %ile)
VCEL
SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
13th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NTLA nor VCEL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.